CLPT News and Press, ClearPoint Neuro, Inc. From 01/12/26

2026-01-12 08:43:47 ET More on ClearPoint Neuro, Inc. ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript ClearPoint Neuro: CRO Facility Should Reaccelerate Growth ClearPoint Neuro, Inc. GAAP EPS of -$0.21 misses by $0.01, revenue of $8.86M misses by $0.74...

The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise n...

Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 20, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global devi...

2025-11-12 17:21:36 ET ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST... Read the full article on Seeking Alpha For further details see: ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript

2025-11-12 15:55:06 ET ClearPoint Neuro ( CLPT ) reported soft results in the third quarter, adding pressure to a recent decline in the share price. The reason for weak growth in recent quarters isn't really clear, but quarterly volatility should be expected given the nascent state of t...

2025-11-06 17:56:16 ET More on ClearPoint Neuro, Inc. ClearPoint Neuro: AMT-130 Highlights A Bright Future ClearPoint Neuro: Selling The Tools For Brain Therapies ClearPoint Neuro: Biopharma Momentum Continues To Build ClearPoint Neuro outlines global expansi...

Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire / November 6, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global devi...

Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment of Intracranial Bleeding SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 6, 2025 / ...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will participate in the following investor confe...